PMID- 29108879
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20171214
IS  - 1096-0945 (Electronic)
IS  - 0014-4800 (Linking)
VI  - 103
IP  - 3
DP  - 2017 Dec
TI  - Remyelination modulators in multiple sclerosis patients.
PG  - 237-241
LID - S0014-4800(17)30311-8 [pii]
LID - 10.1016/j.yexmp.2017.11.004 [doi]
AB  - Multiple Sclerosis (MS) is a complex autoimmune neuro-inflammatory disorder 
      characterized by persistent MS plaques in the central nervous system. Resolution 
      of MS plaques is dependent on the remyelination competence of surviving 
      oligodendrocytes and surrounding environment. Here, we assessed myelination 
      modulators in a 100 MS patients against 77 healthy controls. Plasma fractions 
      were used for the assessment of insulin growth factor binding protein1 (IGFBP1), 
      brain-derived neurotrophic factor (BDNF), and lipocalin2 (LCN2) using a Luminex 
      multiplex assay, whereas neurofilament light chain (NF-L) was assessed with an 
      enzyme-linked immunosorbent assay. Circulating levels of IGFBP1, LCN2 and NF-L 
      were significantly higher in MS patients (p<0.01). Whereas BDNF levels were 
      significantly lower in MS patients (p=0.014). MS Female patients had 
      significantly higher levels of IGFBP1 compared to male MS patients (p=0.006). MS 
      patients treated with fingolimod had higher LCN2 levels compared to those on 
      natalizumab (r=0.25, p=0.03). Higher NF-L levels associated with clinically 
      isolated syndrome's (CIS) conversion into MS (p=0.002). We conclude that low BDNF 
      and high LCN2 and NF-L levels are associated with MS pathogenesis, and high 
      IGFBP1level is a biomarker for female MS only, suggesting different MS 
      progression pathways between the sexes. LCN2 is a candidate predictor of response 
      to natalizumab treatment, and NF-L is a candidate predictor of CIS conversion 
      into MS.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Al-Temaimi, Rabeah
AU  - Al-Temaimi R
AD  - Human Genetics Unit, Department of Pathology, Faculty of Medicine, Kuwait 
      University, Jabriya, Kuwait. Electronic address: rabeah@hsc.edu.kw.
FAU - AbuBaker, Jehad
AU  - AbuBaker J
AD  - Biochemistry and Molecular Biology Unit Dasman Diabetes Institute, Kuwait City, 
      Kuwait. Electronic address: jehad.abubakr@dasmaninstitute.org.
FAU - Al-Khairi, Irina
AU  - Al-Khairi I
AD  - Biochemistry and Molecular Biology Unit Dasman Diabetes Institute, Kuwait City, 
      Kuwait. Electronic address: irina.alkhairi@dasmaninstitute.org.
FAU - Alroughani, Raed
AU  - Alroughani R
AD  - Division of Neurology, Department of Medicine, Amiri Hopsital, Sharq, Kuwait.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171108
PL  - Netherlands
TA  - Exp Mol Pathol
JT  - Experimental and molecular pathology
JID - 0370711
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (IGFBP1 protein, human)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 1)
RN  - 0 (LCN2 protein, human)
RN  - 0 (Lipocalin-2)
RN  - 0 (Natalizumab)
RN  - 0 (Neurofilament Proteins)
RN  - 0 (neurofilament protein L)
RN  - G926EC510T (Fingolimod Hydrochloride)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Demyelinating Diseases/blood/drug therapy/physiopathology
MH  - Female
MH  - Fingolimod Hydrochloride/administration & dosage
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Protein 1/*blood
MH  - Lipocalin-2/*blood
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis/*blood/drug therapy/physiopathology
MH  - Natalizumab/administration & dosage
MH  - Neurofilament Proteins/*blood
MH  - Remyelination/drug effects
MH  - Sex Characteristics
OTO - NOTNLM
OT  - Brain-derived neurotrophic factor
OT  - Insulin growth factor binding protein 1
OT  - Lipocalin 2
OT  - Multiple sclerosis
OT  - Neurofilament light chain
EDAT- 2017/11/08 06:00
MHDA- 2017/12/05 06:00
CRDT- 2017/11/08 06:00
PHST- 2017/06/01 00:00 [received]
PHST- 2017/09/03 00:00 [revised]
PHST- 2017/11/01 00:00 [accepted]
PHST- 2017/11/08 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/11/08 06:00 [entrez]
AID - S0014-4800(17)30311-8 [pii]
AID - 10.1016/j.yexmp.2017.11.004 [doi]
PST - ppublish
SO  - Exp Mol Pathol. 2017 Dec;103(3):237-241. doi: 10.1016/j.yexmp.2017.11.004. Epub 
      2017 Nov 8.